| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Oaktree Capital · Howard Marks | $37.8M | 0.52% | 39.21M | New | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $1.6M | 0.01% | 77.09K | +50% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ENOV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Mcdonald DamienChief Executive Officer | Purchase at price 19.15 per share. | 13K | $249.62K |
| Sep 3, 2026 | Engert OliverOfficer | Purchase at price 18.80 per share. | 2.7K | $50.01K |
| Sep 2, 2026 | Engert OliverOfficer | Purchase at price 19.46 - 20.32 per share. | 7.6K | $149.97K |
| Jun 29, 2026 | Ortiz ChristineDirector | Stock Award(Grant) at price 0.00 per share. | 846 | — |
| Jun 14, 2026 | Engert OliverOfficer | Purchase at price 20.92 per share. | 1K | $20.92K |
| Jun 10, 2026 | Engert OliverOfficer | Stock Award(Grant) at price 20.99 per share. | 1.2K | $25.19K |
| Jun 10, 2026 | Engert OliverOfficer | Purchase at price 20.99 - 21.75 per share. | 1.2K | $25.95K |
| Jun 9, 2026 | Engert OliverOfficer | Purchase at price 23.00 per share. | 1K | $23.00K |
| May 31, 2026 | Engert OliverOfficer | Purchase at price 22.22 per share. | 1K | $22.22K |
| May 18, 2026 | Shirley Brady R.Director | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Okala PhilipDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Vinnakota RajivDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Perfall A ClaytonDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Wienbar Sharon LDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Lalor Angela SDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Kelly Liam JDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Bodem Barbara WDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| May 18, 2026 | Ortiz ChristineDirector | Stock Award(Grant) at price 0.00 per share. | 9.3K | — |
| Mar 30, 2026 | Ortiz ChristineDirector | Stock Award(Grant) at price 0.00 per share. | 770 | — |
| Mar 12, 2026 | Engert OliverOfficer | Purchase at price 23.74 per share. | 1K | $23.74K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.3 | 15.6 | -10.7 | 3.0 | -3.2 | -8.7 | 40.8 | -15.6 | -25.7 | 3.0 | −29.4% | ||
| 2025 | 7.1 | -17.7 | -1.1 | -9.5 | -9.5 | 0.2 | -14.5 | 15.3 | -1.8 | 3.0 | -3.1 | -12.0 | −39.3% |
| 2024 | 4.8 | 1.9 | 4.4 | -11.6 | -9.0 | -10.1 | 5.4 | -2.2 | -7.6 | -4.1 | 18.3 | -10.1 | −21.7% |
| 2023 | 17.6 | -8.5 | -7.2 | 8.9 | -9.5 | 21.6 | -0.3 | -12.3 | -5.9 | -13.0 | 7.8 | 13.3 | +4.7% |
| 2022 | -10.6 | -2.2 | -1.0 | -5.3 | 2.3 | -17.1 | 8.6 | -15.2 | -9.0 | 7.3 | 9.5 | -1.1 | −32.4% |
| 2021 | -2.9 | 19.5 | -1.2 | 3.1 | -2.2 | 3.6 | 0.2 | 5.0 | -4.7 | 12.5 | -10.0 | -1.0 | +20.2% |
| 2020 | -3.4 | -4.8 | -40.8 | 30.3 | 8.8 | -0.6 | 4.2 | 14.4 | -5.8 | -13.3 | 32.7 | 6.0 | +5.1% |
| 2019 | 18.4 | 6.9 | 12.2 | 1.7 | -16.8 | 11.7 | -1.2 | -1.7 | 6.8 | 15.6 | 0.3 | 8.0 | +74.1% |
| 2018 | 1.0 | -20.6 | 0.3 | -2.8 | -1.4 | 0.2 | 5.4 | 8.1 | 3.3 | -22.3 | -11.0 | -16.2 | −47.2% |
| 2017 | 8.5 | -2.4 | 3.2 | 3.1 | 0.2 | -2.9 | 4.9 | -3.4 | 4.4 | 0.2 | -10.7 | 6.3 | +10.3% |
| 2016 | -5.2 | 14.3 | 13.0 | 13.4 | -16.5 | -2.3 | 11.0 | 1.1 | 5.9 | 1.1 | 18.3 | -4.5 | +53.9% |
| 2015 | -12.1 | 16.3 | -9.4 | 3.9 | 1.6 | -8.4 | -17.4 | 1.7 | -22.9 | -9.9 | 0.4 | -13.7 | −54.7% |
| 2014 | -5.4 | 18.1 | 0.3 | 0.9 | 1.1 | 2.4 | -15.5 | 1.0 | -10.4 | -4.5 | -5.2 | 0.1 | −19.0% |
| 2013 | 10.6 | -2.7 | 7.2 | 0.3 | 6.9 | 4.4 | 1.8 | -1.8 | 8.4 | -0.9 | 3.8 | 9.7 | +57.8% |
| 2012 | 6.6 | 12.1 | 3.6 | -3.8 | -16.4 | -2.7 | 5.0 | 13.6 | 11.5 | -6.2 | 13.4 | 3.5 | +41.7% |
| 2011 | 1.2 | 19.0 | 3.5 | -4.8 | 3.1 | 10.1 | 9.2 | -7.4 | -19.2 | 24.7 | 16.0 | -2.8 | +54.7% |
| 2010 | -6.4 | 0.5 | 3.9 | 10.9 | -8.6 | -12.7 | 24.4 | -3.6 | 19.1 | 8.1 | 5.0 | 9.1 | +52.9% |
| 2009 | -12.2 | -20.3 | -5.5 | 25.6 | -5.7 | -5.2 | 22.7 | 11.9 | 0.3 | 2.4 | 14.2 | -3.1 | +15.9% |
| 2008 | 1.2 | 8.8 | -9.9 | -32.0 | -49.0 | 12.2 | 8.7 | −58.1% |
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
Buy / hold / sell counts